Investigate immuno-landscape in adenocarcinoma of the gastroesophageal junction (AEG)

Adenocarcinoma of the gastroesophageal junction (AEG) is an aggressive malignancy with rising incidence worldwide. Despite advances in surgical techniques and systemic therapies, patient outcomes remain limited, highlighting the need for a deeper understanding of tumor biology. One key factor influencing disease progression and treatment response is the tumor immune microenvironment. The immuno-landscape of AEG—including the composition, spatial distribution, and functional status of immune cells—plays a crucial role in tumor growth, metastasis, and response to therapy, particularly emerging immuno-oncology approaches.

Our research focuses on characterizing the immune microenvironment in AEG using a combination of histopathology, immunohistochemistry, molecular profiling, and bioinformatic analysis. We aim to identify key immune cell populations, checkpoint molecule expression, and inflammation-related biomarkers that correlate with clinical outcomes. By mapping tumor–immune interactions and defining immune phenotypes, this work seeks to uncover prognostic indicators and potential therapeutic targets. Ultimately, understanding the immuno-landscape in AEG will support the development of personalized immuno-oncology strategies, improve patient stratification for therapy, and contribute to more effective management of this challenging malignancy.